BS_G00FHF3Q
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 109.19999999999999
- os_event
- true
- age_years
- 13.904
- sex
- M
- race
- White
- new_clusters
- C6
- umap1_2d
- 3.485968779
- umap2_2d
- 6.47872927
- umap1_3d
- 2.188813577
- umap2_3d
- -0.862441451
- umap3_3d
- -4.705776163
- dataset
- Med-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- DNA_REPAIR+0.400
- E2F_TARGETS+0.340
- INTERFERON_ALPHA_RESPONSE+0.340
- PI3K_AKT_MTOR_SIGNALING+0.300
- INTERFERON_GAMMA_RESPONSE+0.270
- PROTEIN_SECRETION+0.260
- G2M_CHECKPOINT+0.240
- OXIDATIVE_PHOSPHORYLATION+0.230
- MITOTIC_SPINDLE+0.170
- HEME_METABOLISM+0.140
Top 10 suppressed
- HYPOXIA-0.260
- PANCREAS_BETA_CELLS-0.230
- INFLAMMATORY_RESPONSE-0.220
- KRAS_SIGNALING_DN-0.210
- TNFA_SIGNALING_VIA_NFKB-0.210
- ESTROGEN_RESPONSE_EARLY-0.190
- MYOGENESIS-0.180
- ANDROGEN_RESPONSE-0.150
- ANGIOGENESIS-0.140
- SPERMATOGENESIS-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG833 | — | — | 0.759 |
| 2 | MNG1021 | — | — | 0.724 |
| 3 | MNG137 | — | — | 0.713 |
| 4 | MNG605 | — | — | 0.708 |
| 5 | 88318 | EPN | Supratentorial EPN | 0.706 |
| 6 | MNG398 | — | — | 0.704 |
| 7 | 88302 | EPN | Supratentorial EPN | 0.699 |
| 8 | BS_W80TJC27 | Supratentorial Ependymoma | — | 0.698 |
| 9 | MNG987 | — | — | 0.696 |
| 10 | SRR12202424 | — | — | 0.694 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.340 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.340 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.270 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| MYC_TARGETS_V1 | 0.130 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.120 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.110 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| COMPLEMENT | 0.090 | Inavolisib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.060 | Inavolisib | — uncovered |